Abstract

Flosequinan (Manoplax – Boots), an arteriolar- and veno-dilator, is licensed in the UK for the treatment of patients with chronic congestive heart failure (CHF), to be used with a diuretic and, where appropriate, an angiotensin converting enzyme (ACE) inhibitor and a cardiac glycoside. Originally, it was marketed in 50 and 100mg tablet strengths. However, the 100mg tablet has now been withdrawn because daily doses of 100mg may increase mortality. Does flosequinan have a place in the management of CHF?